EECP for Practitioners
Foundations

EECP has been FDA-cleared since 1995, carries Class IIb AHA/ACC recommendation for refractory angina, is covered by Medicare under NCD 20.20, and is routinely deployed as first-line therapy in China and India. In the United States, fewer than 5% of eligible patients ever receive it. Before we teach you how EECP works, we have to explain why you've probably never prescribed it.

You know the cardiac cycle. You know the NO pathway. You understand shear stress and endothelial function. This module shows you how EECP exploits all of them, and what that implies about who it can help.

Understanding why EECP looks the way it looks — and why its adoption followed the path it did — requires knowing where it came from. The short version: Harvard, the 1950s, a hydraulic system that didn't work well enough, a long dormancy, a Chinese renaissance, and a slow re-arrival in the West.

Four indications carry FDA clearance and are covered by Medicare under NCD 20.20. Before we discuss off-label use, you need to know exactly what the trials show for the uses EECP is officially recommended for.

This is where the course gets useful in a way most CME doesn't. The mechanism of EECP predicts benefit in a long list of conditions that the trial infrastructure never got around to studying rigorously. Some of those predictions are well-supported. Some are speculative. A responsible practitioner has to know which is which.

EECP is remarkably safe. It is not universally safe. This module covers the absolute and relative contraindications, the nuance in the grey-zone cases, and gives you a working triage tool for the patients you'll actually see.

Everything up to this point is theory. This module is practice: how to have the conversation with a patient, how to choose a provider, how to handle the common objections, and how to think about EECP as one tool in a larger clinical toolkit.